Overview

Safety and Efficacy Study in Hepatitis C Patients With PHN121

Status:
Terminated
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety, tolerability and efficacy of escalating dose of PHN121 when administered orally in non-responder hepatitis C genotype 1 patients
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
PhytoHealth Corporation